Bortezomib exerts its anti-myeloma effect by reversibly inhibiting the proteasome through various mechanisms,and it is currently the first-line drug for the treatment of multiple myeloma in China.Bortezomib-induced peripheral neuropathy is one of the most common dose-limiting adverse reactions in the treatment process,which seriously affects the quality of life of patients,leading to dose reduction or even drug withdrawal.How to reduce or prevent Bortezomib-induced peripheral neuropathy remains a challenging problem in the treatment of multiple myeloma.Based on this,this article reviews the pathogenesis of Bortezomib-induced peripheral neuropathy from the perspectives of Schwann cells,neurons,astrocytes,macrophages,and other aspects.
NETL
NSTL
万方数据
